SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts assign SAB Biotherapeutics an average rating of Moderate Buy from eight firms (2 sell, 5 buy, 1 strong buy) with an average 12‑month price target of $10.50.
• Individual price targets and views vary widely—from $7 (UBS, HC Wainwright) up to $14 (Chardan) and $13 (Rodman & Renshaw)—indicating mixed sentiment among analysts.
• SABS shares trade around $3.47 with a market cap of $176.8M; the company reported a ($0.46) EPS miss for the quarter and analysts forecast roughly -0.72 EPS for the current fiscal year.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.50.

Several equities research analysts have commented on the stock. UBS Group assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Rodman & Renshaw began coverage on SAB Biotherapeutics in a research report on Thursday, April 2nd. They set a "buy" rating and a $13.00 price target for the company. HC Wainwright decreased their price target on SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, March 10th. Finally, Chardan Capital raised their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, March 11th.

Institutional Trading of SAB Biotherapeutics

Large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP purchased a new stake in SAB Biotherapeutics during the third quarter worth about $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $34,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $40,000. Finally, State Street Corp purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 7.82% of the company's stock.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.47 on Friday. The firm has a 50-day moving average of $3.87 and a 200-day moving average of $3.75. The company has a market cap of $176.80 million, a P/E ratio of -1.50 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. SAB Biotherapeutics has a one year low of $1.53 and a one year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Equities research analysts forecast that SAB Biotherapeutics will post -0.72 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.